Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 | Zendy

Ariel Hammerman | Zendy; Ruslan Sergienko | Zendy; Michael Friger | Zendy; Tanya Beckenstein | Zendy; Alon Peretz | Zendy; Doron Netzer | Zendy; Shlomit Yaron | Zendy; Ronen Arbel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19

Author(s) -

Ariel Hammerman,

Ruslan Sergienko,

Michael Friger,

Tanya Beckenstein,

Alon Peretz,

Doron Netzer,

Shlomit Yaron,

Ronen Arbel

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2119497

Subject(s) - covid-19 , medicine , vaccination , immunity , coronavirus , virology , intensive care medicine , immunology , disease , immune system , infectious disease (medical specialty) , outbreak

The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity lasts. Current guidelines recommend vaccination of recovered patients even though data regarding vaccine effectiveness in such cases are still limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research